Investments
27Portfolio Exits
2Funds
1Expert Collections containing LYZZ Capital
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find LYZZ Capital in 1 Expert Collection, including Pharma Startups.
Pharma Startups
5,090 items
Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.
Latest LYZZ Capital News
Jul 17, 2021
Wugen , a Sant Louis MO- and San Diego CA-based clinical stage biotechnology company, raised $172M in Series B funding. The round was led by Abingworth and Tybourne Capital Management with participation from Fidelity Management & Research Company, Intermediate Capital Group (ICG), Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital, Falcon Edge Capital, RiverVest Venture Partners, LYZZ Capital, Lightchain Capital. The company intends to use the funds to support the clinical development of its memory natural killer (NK) cell platform and advance ongoing trials for patients with severe acute myelogenous leukemia (AML) and other oncology indications, as well as to advance its broader pipeline of next-generation products into the clinic. Led by Dan Kemp, Wugen provides a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory natural killer (NK) cell therapies to treat a broad range of hematological and solid tumor malignancies. In addition, the company is developing a pipeline of programs targeting solid tumor indications. FinSMEs 17/07/2021
LYZZ Capital Investments
27 Investments
LYZZ Capital has made 27 investments. Their latest investment was in Wugen as part of their Series B on July 7, 2021.
LYZZ Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
7/15/2021 | Series B | Wugen | $172M | No | 6 | |
6/10/2021 | Series A | Onchilles Pharma | $7M | Yes | 2 | |
6/9/2021 | Series B | Qingyun Technology | No | 4 | ||
6/8/2021 | Series A - II | |||||
3/29/2021 | Seed VC |
Date | 7/15/2021 | 6/10/2021 | 6/9/2021 | 6/8/2021 | 3/29/2021 |
|---|---|---|---|---|---|
Round | Series B | Series A | Series B | Series A - II | Seed VC |
Company | Wugen | Onchilles Pharma | Qingyun Technology | ||
Amount | $172M | $7M | |||
New? | No | Yes | No | ||
Co-Investors | |||||
Sources | 6 | 2 | 4 |
LYZZ Capital Portfolio Exits
2 Portfolio Exits
LYZZ Capital has 2 portfolio exits. Their latest portfolio exit was Microtech Medical on October 19, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/19/2021 | IPO | 3 | |||
Date | 10/19/2021 | |
|---|---|---|
Exit | IPO | |
Companies | ||
Valuation | ||
Acquirer | ||
Sources | 3 |
LYZZ Capital Fund History
1 Fund History
LYZZ Capital has 1 fund, including Jiangsu Jiequan Lyzz Healthcare Venture Capital Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
Jiangsu Jiequan Lyzz Healthcare Venture Capital Fund | Multi-Stage Venture Capital | 1 |
Closing Date | |
|---|---|
Fund | Jiangsu Jiequan Lyzz Healthcare Venture Capital Fund |
Fund Type | Multi-Stage Venture Capital |
Status | |
Amount | |
Sources | 1 |
LYZZ Capital Team
1 Team Member
LYZZ Capital has 1 team member, including current Managing Partner, Kevin Li.
Name | Work History | Title | Status |
|---|---|---|---|
Kevin Li | Toucan Capital | Managing Partner | Current |
Name | Kevin Li |
|---|---|
Work History | Toucan Capital |
Title | Managing Partner |
Status | Current |